A Phase 4 interventional study of Ocrelizumab in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by Hoffmann-La Roche. Completed at 8 sites in 3 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 23rd largest by enrollment, is one of 2 that started in 2021, is one of 11 in phase 4, and was the 17th registered.
3,272 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2021.
This study's enrollment of 26 is below the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 170 across the 27 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Multiple Sclerosis by Hoffmann-La Roche: 6 open now, 17 under way, 7 of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 27th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 in phase 4, and was the 20th registered.
Hoffmann-La Roche’s Multiple Sclerosis studies by the year they started, since 2004.
1 of the studies testing ocrelizumab in Multiple Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04466150University of California, San FranciscoImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, from their registry updates:
Among Hoffmann-La Roche’s 35 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.
Inclusion Criteria:
Exclusion Criteria related to the Mother:
Exclusion Criteria related to the Infant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.
Drug: Ocrelizumab
Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion
Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose). The percentage of infants with B cell levels below LLN are reported with the two-sided Clopper Pearson 95% confidence interval (CI). B-cell reference ranges by week of life (absolute and percentage counts) are defined by Borriello et al. 2022.
Time frame: At Day 30
Estimated Average Oral Daily Infant Dosage (ADID)
ADID was calculated as the arithmetic mean of the mother's daily ocrelizumab milk concentration (micrograms/milliliters \[µg/mL\]) over 60 days post-ocrelizumab infusion 1 multiplied by an estimated infant milk intake of 150 milliliters/kilograms/day (mL/kg/day) and based on the weight \[kilograms (kg)\] recorded at the Day 30 visit. Ocrelizumab concentrations reported as below the lower limit of quantification \[LLQ=160 nanograms/millilitres (ng/mL)\] are imputed to zero for the calculation ADID.
Time frame: Up to Day 60
Absolute CD19+ B Cell Count in the Infant
Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).
Time frame: At Day 30
Percentage of CD19+ B Cell in the Infant
Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).
Time frame: At Day 30
Area Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk
Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Average Concentration of Ocrelizumab in Breastmilk (Cmean)
Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Maximum Concentration (Cmax) of Ocrelizumab in Breastmilk
Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Time of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk
Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Estimated Maximum Oral Daily Infant Dosage (MDID)
MDID was calculated at the subject level as the peak ocrelizumab milk concentration (μg/mL) multiplied by an estimated infant milk intake of 150 mL/kg/day measured over 60 days after the mother's first postpartum ocrelizumab infusion.
Time frame: Up to Day 60
Average Relative Infant Dose (RID)
Average RID over 60 days was calculated as the ADID (mg/kg/day) divided by the maternal dosage (mg/kg/day) over 60 days multiplied by 100.
Time frame: Up to Day 60
Serum Concentration of Ocrelizumab in the Infant at Day 30
Serum concentration of ocrelizumab in the infant measured at Day 30 after the mother's first ocrelizumab postpartum infusion. Concentrations reported as below the lower limit of quantification (LLQ=156 ng/mL) are set to zero for calculation of summary statistics.
Time frame: At Day 30
Percentage of Mothers With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Time frame: Up to approximately 73.3 weeks after first ocrelizumab dose
Percentage of Infants With AEs
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Time frame: Up to approximately 73.3 weeks after first ocrelizumab dose administered to mother
Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Measles, Mumps, and Rubella (MMR) Vaccination
The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination
The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination
The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to MMR Vaccination
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 RU/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to DTP Vaccine
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine
The immune response to Hib vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to Hib Vaccine
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine
The immune response to HBV vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to HBV Vaccine
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Pneumococcal Capsular Polysaccharide, Serotypes, IgG Antibody in Response to 13-valent Pneumococcal Conjugate Vaccine (PCV-13)
The immune response to PCV-13 vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to PCV-13
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
A total of 13 mother-infant pairs took part in the study across 7 sites in the United States, Spain, and the United Kingdom from 16 September 2021 to 13 January 2025.
| Milestone | Mothers | Infants |
|---|---|---|
| Started | 13 | 13 |
| Completed | 12 | 12 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Mothers | Infants |
|---|---|---|
| Started | 12 | 12 |
| Completed | 11 | 11 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose). The percentage of infants with B cell levels below LLN are reported with the two-sided Clopper Pearson 95% confidence interval (CI). B-cell reference ranges by week of life (absolute and percentage counts) are defined by Borriello et al. 2022.
| percentage of participants | Infants |
|---|---|
| Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion | 0 (0 to 30.85) |
ADID was calculated as the arithmetic mean of the mother's daily ocrelizumab milk concentration (micrograms/milliliters \[µg/mL\]) over 60 days post-ocrelizumab infusion 1 multiplied by an estimated infant milk intake of 150 milliliters/kilograms/day (mL/kg/day) and based on the weight \[kilograms (kg)\] recorded at the Day 30 visit. Ocrelizumab concentrations reported as below the lower limit of quantification \[LLQ=160 nanograms/millilitres (ng/mL)\] are imputed to zero for the calculation ADID.
| micrograms (µg) | Mothers |
|---|---|
| Estimated Average Oral Daily Infant Dosage (ADID) | 64.50 (21.415 to 107.587) |
Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).
| cells per microliter (cells/µL) | Infants |
|---|---|
| Absolute CD19+ B Cell Count in the Infant | 1431.50 (869.0 to 2241.0) |
Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).
| percentage of cells | Infants |
|---|---|
| Percentage of CD19+ B Cell in the Infant | 21.80 (10.0 to 31.7) |
| micrograms/millilitres*day (μg/mL*day) | Mothers |
|---|---|
| Area Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk | 3.98 ± 4.93 |
| μg/mL | Mothers |
|---|---|
| Average Concentration of Ocrelizumab in Breastmilk (Cmean) | 0.074 ± 0.077 |
| μg/mL | Mothers |
|---|---|
| Maximum Concentration (Cmax) of Ocrelizumab in Breastmilk | 0.18 ± 0.15 |
| days | Mothers |
|---|---|
| Time of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk | 3.97 (0.00 to 59.9) |
MDID was calculated at the subject level as the peak ocrelizumab milk concentration (μg/mL) multiplied by an estimated infant milk intake of 150 mL/kg/day measured over 60 days after the mother's first postpartum ocrelizumab infusion.
| µg | Mothers |
|---|---|
| Estimated Maximum Oral Daily Infant Dosage (MDID) | 153.20 ± 137.15 |
Average RID over 60 days was calculated as the ADID (mg/kg/day) divided by the maternal dosage (mg/kg/day) over 60 days multiplied by 100.
| percentage | Mothers |
|---|---|
| Average Relative Infant Dose (RID) | 0.50 ± 0.58 |
Serum concentration of ocrelizumab in the infant measured at Day 30 after the mother's first ocrelizumab postpartum infusion. Concentrations reported as below the lower limit of quantification (LLQ=156 ng/mL) are set to zero for calculation of summary statistics.
| µg/mL | Infants |
|---|---|
| Serum Concentration of Ocrelizumab in the Infant at Day 30 | NA ± NA |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
| percentage of participants | Mothers |
|---|---|
| Percentage of Mothers With Adverse Events (AEs) | 76.9 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
| percentage of infants | Infants |
|---|---|
| Percentage of Infants With AEs | 92.3 |
The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.
| mIU/mL | Infants |
|---|---|
| Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Measles, Mumps, and Rubella (MMR) Vaccination | 2590.91 ± 2210.74 |
The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.
| RU/mL | Infants |
|---|---|
| Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination | 54.19 ± 34.72 |
The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.
| IU/mL | Infants |
|---|---|
| Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination | 94.21 ± 51.39 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 RU/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL.
| percentage of infants | Infants |
|---|---|
| Measles, IgG | 100 |
| Mumps, IgG | 77.8 |
| Rubella, IgG | 100 |
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| IU/mL | Infants |
|---|---|
| Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine | 1.94 ± 3.13 |
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
| COI | Infants |
|---|---|
| Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine | 1.12 ± 0.82 |
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| IU/mL | Infants |
|---|---|
| Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine | 1.23 ± 0.43 |
The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
| percentage of infants | Infants |
|---|---|
| Corynebacterium Diphtheriae, IgG | 100 |
| Bordetella Pertussis, IgG | 50 |
| Tetanus Toxoid, IgG | 100 |
The immune response to Hib vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| micrograms per milliliter (ug/mL) | Infants |
|---|---|
| Mean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine | 3.45 ± 4.21 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.
| percentage of infants | Infants |
|---|---|
| Percentage of Infants With Positive Humoral Response to Hib Vaccine | 88.9 |
The immune response to HBV vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| mIU/mL | Infants |
|---|---|
| Mean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine | 1158.01 ± 1263.32 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.
| percentage of infants | Infants |
|---|---|
| Percentage of Infants With Positive Humoral Response to HBV Vaccine | 100 |
The immune response to PCV-13 vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| ug/mL | Infants |
|---|---|
| Pneumococcal Capsular Polysaccharide, Serotype 1, IgG | 4.80 ± 6.38 |
| Pneumococcal Capsular Polysaccharide, Serotype 3, IgG | 2.56 ± 3.16 |
| Pneumococcal Capsular Polysaccharide, Serotype 4, IgG | 8.28 ± 9.18 |
| Pneumococcal Capsular Polysaccharide, Serotype 5, IgG | 9.98 ± 15.72 |
| Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG | 27.28 ± 34.50 |
| Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG | 27.02 ± 70.85 |
| Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG | 9.44 ± 14.11 |
| Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG | 4.21 ± 3.66 |
| Pneumococcal Capsular Polysaccharide, Serotype 14, IgG | 14.93 ± 14.49 |
| Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG | 9.62 ± 11.47 |
| Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG | 1.70 ± 1.41 |
| Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG | 45.83 ± 80.11 |
| Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG | 10.50 ± 13.17 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml.
| percentage of infants | Infants |
|---|---|
| Pneumococcal Capsular Polysaccharide, Serotype 1, IgG | 80 |
| Pneumococcal Capsular Polysaccharide, Serotype 3, IgG | 70 |
| Pneumococcal Capsular Polysaccharide, Serotype 4, IgG | 80 |
| Pneumococcal Capsular Polysaccharide, Serotype 5, IgG | 90 |
| Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG | 100 |
| Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG | 80 |
| Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG | 100 |
| Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG | 90 |
| Pneumococcal Capsular Polysaccharide, Serotype 14, IgG | 100 |
| Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG | 80 |
| Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG | 60 |
| Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG | 100 |
| Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG | 80 |
Collected over Mothers and Infants: Up to approximately 73.3 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mothers | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Infants | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Event | Mothers | Infants |
|---|---|---|
| COVID-19Infections and infestations | 6/13 | 4/13 |
| PyrexiaGeneral disorders | 1/13 | 3/13 |
| Ear infectionInfections and infestations | 0/13 | 3/13 |
| NasopharyngitisInfections and infestations | 3/13 | 3/13 |
| Infusion related reactionInjury, poisoning and procedural complications | 3/13 | 0/13 |
| PainGeneral disorders | 2/13 | 1/13 |
| BronchiolitisInfections and infestations | 0/13 | 2/13 |
| Hand-foot-and-mouth diseaseInfections and infestations | 0/13 | 2/13 |
| MastitisInfections and infestations | 2/13 | 0/13 |
| Upper respiratory tract infectionInfections and infestations | 2/13 | 2/13 |
Safety Analysis Set Mothers (SAFM) included all mothers who met the eligibility criteria and received any post-partum dose of ocrelizumab. Safety Analysis Set Infants (SAFI) included all the infants of women in the Full Analysis Set Mothers (FASM) population. As consent for race and ethnicity was not obtained, this data has not been reported.
| Age, Customized(Participants) | Mothers | Infants | Total |
|---|---|---|---|
| Preterm newborn infants (gestational age <37 weeks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 8 | 8 |
| Infants and toddlers (28 days-23 months) | 0 | 5 | 5 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 13 | 0 | 13 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Mothers | Infants | Total |
|---|---|---|---|
| Female | 13 | 6 | 19 |
| Male | 0 | 7 | 7 |
| Race/Ethnicity, Customized(Participants) | Mothers | Infants | Total |
|---|---|---|---|
| Not reported | 13 | 13 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Sep 2021 to primary completion in Mar 2024, 30 months.
Results were first posted in Apr 2025, 1 year after primary completion.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 30 months is close to that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab